文献速递临床试验与 GCP流行病学与生物统计

家庭肠外营养患者金黄色葡萄球菌长期去定植:随机多中心试验方案

Long-term Staphylococcus aureus decolonization in patients on home parenteral nutrition: study protocol for a randomized multicenter trial.
PubMed 文献 · Trials · 2018-06-28

长期肠衰竭患者接受家庭肠外营养(HPN)时面临金黄色葡萄球菌菌血症(SAB)终身风险,而HPN人群中最佳去定植策略缺乏证据。CARRIER试验为随机、开放标签、多中心临床研究,在荷兰和丹麦医院纳入138例携带金黄色葡萄球菌的成人HPN患者,比较「搜索与摧毁」策略与持续抑制策略,主要结局为1年内金黄色葡萄球菌完全根除的患者比例。

要点

  • HPN患者因中心静脉导管暴露于终身SAB风险,SAB威胁导管和患者生存。
  • CARRIER试验比较短期系统性抗生素与慢性局部抗生素两种去定植策略。
  • 主要结局为1年内金黄色葡萄球菌完全根除的患者比例。

核心结论

  • CARRIER试验旨在确定HPN患者中最安全有效的长期金黄色葡萄球菌去定植策略,可能减少SAB相关感染。

研究设计与样本

  • 随机、开放标签、多中心临床试验,在荷兰和丹麦治疗HPN患者的医院开展,共纳入138例携带金黄色葡萄球菌的成人HPN患者。
  • 患者随机分配至搜索与摧毁(SD)策略(快速短程系统性抗生素治疗)或持续抑制(CS)策略(重复慢性局部抗生素治疗)。

主要发现

  • 原文未报告研究结果,仅描述研究方案设计。

关键数值与推荐

  • 主要结局指标为1年期间金黄色葡萄球菌完全根除的患者比例。
  • 次要结局包括成功根除时间、长期抗菌药物耐药性、不良事件、患者依从性、(金黄色葡萄球菌)感染发生率、导管移除、死亡率、金黄色葡萄球菌传播途径、生活质量和医疗费用。

临床怎么用

  • 原文未报告临床实践推荐,研究结果预期将影响日常临床实践并可能减少金黄色葡萄球菌相关感染。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with long-term intestinal failure are usually treated by means of home parenteral nutrition (HPN) where they administer their nutritional formulation intravenously via a central venous access device (mostly a catheter). This implies that such patients are exposed to a lifelong risk of developing Staphylococcus aureus bacteremia (SAB). SAB poses a threat to both catheter and patient survival and may lead to frequent hospitalization and a permanent loss of vascular access. In other clinical settings, S. aureus carriage eradication has been proven effective in the prevention of S. aureus infections. Unfortunately, there is a complete lack of evidence in HPN support on the most effective and safe S. aureus decolonization strategy in S. aureus carriers. We hypothesized that long-term S. aureus decolonization in HPN patients can only be effective if it is aimed at the whole body (nasal and extra-nasal) and is given chronically or repeatedly on indication. Besides this, we believe that S. aureus carriage among caregivers, who are in close contact with the patient, are of great importance in the S. aureus transmission routes. METHODS/DESIGN: The CARRIER trial is a randomized, open-label, multicenter clinical trial in Dutch and Danish hospitals that treat patients on HPN. A total of 138 adult HPN patients carrying S. aureus will be randomly assigned to a search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment, or a continuous suppression (CS) strategy, a repeated chronic topical antibiotic treatment. The primary outcome measure is the proportion of patients in whom S. aureus is totally eradicated during a 1-year period. Secondary outcomes are time to successful eradication, long-term antimicrobial resistance, adverse events, patient compliance, incidence of (S. aureus) infections, catheter removals, mortality rates, S. aureus transmission routes, quality of life, and health care costs. DISCUSSION: The CARRIER trial is designed to identify the most safe and effective long-term S. aureus carriage decolonization strategy in HPN patients. This will eventually lead to a better understanding of long-term S. aureus decolonization treatments in general. The results of this study will have a great impact on our daily clinical practice, which eventually may result in less S. aureus-related infections. TRIAL REGISTRATION: ClinicalTrials.gov; NCT03173053 . Registered on 1 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gompelman M, Wouters Y, Kievit W, et al. Long-term Staphylococcus aureus decolonization in patients on home parenteral nutrition: study protocol for a randomized multicenter trial. Trials. 2018. PMID: 29954418. doi:10.1186/s13063-018-2732-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。